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The Centre for Research & Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailanda;
Department of Immunology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailandb; London School of Hygiene and Tropical Medicine, London,
United Kingdomc; Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, United Kingdomd; and Department of Immunology,
National Institute of Infectious Diseases, Tokyo, Japane
Burkholderia pseudomallei is the causative pathogen of melioidosis, of which a major predisposing factor is diabetes mellitus.
Polymorphonuclear neutrophils (PMNs) kill microbes extracellularly by the release of neutrophil extracellular traps (NETs).
PMNs play a key role in the control of melioidosis, but the involvement of NETs in killing of B. pseudomallei remains obscure.
Here, we showed that bactericidal NETs were released from human PMNs in response to B. pseudomallei in a dose- and time-
dependent manner. B. pseudomallei-induced NET formation required NADPH oxidase activation but not phosphatidylinosi-
tol-3 kinase, mitogen-activated protein kinases, or Src family kinase signaling pathways. B. pseudomalleimutants defective in
the virulence-associated Bsa type III protein secretion system (T3SS) or capsular polysaccharide I (CPS-I) induced elevated levels
of NETs. NET induction by suchmutants was associated with increased bacterial killing, phagocytosis, and oxidative burst by
PMNs. Taken together the data imply that T3SS and the capsule may play a role in evading the induction of NETs. Importantly,
PMNs from diabetic subjects released NETs at a lower level than PMNs from healthy subjects. Modulation of NET formation
may therefore be associated with the pathogenesis and control of melioidosis.
Melioidosis is caused by the motile Gram-negative facultativeintracellular pathogen Burkholderia pseudomallei and is en-
demic in Southeast Asia and northern Australia. Melioidosis can
establish with a variety of clinical features, ranging from acute
fulminant septicemia to chronic localized infection. The case fa-
tality rate of patients with severe melioidosis is approximately
50% in Thailand (7, 16, 31, 39). B. pseudomallei infection often
affects individuals with one ormore underlying predisposing con-
ditions associated with impaired immune responses, with thema-
jor risk factor being diabetes mellitus (DM) (18, 25). There has
been much scientific interest in understanding B. pseudomallei-
host interactions at the cellular level, as the organism is resistant to
many antibiotics and no licensed vaccine exists.
Polymorphonuclear neutrophils (PMNs) are highly special-
ized effector cells involved in host inflammatory responses and
immune surveillance (22) and play a key role in control of me-
lioidosis in a murine model (10). A novel antimicrobial activity of
PMNs in which the leukocytes generate neutrophil extracellular
traps (NETs) was recently reported. Upon activation, PMNs can
release NETs composed of chromatin decorated with granular
proteins. NETs possess an antimicrobial activity that can entrap
and damage microbes extracellularly, and it is believed that they
may result from activation of a novel cell death pathway termed
NETosis (4, 5, 13, 34, 35).
The pathways leading to release of NETs are ill defined, but it
has been reported to require activation of one or more of the
phagosomal membrane-bound NADPH oxidase enzyme com-
plexes found in professional phagocytes and B lymphocytes (13).
These enzymes catalyze the production of superoxide anions
(O2
), which in turn produce reactive oxygen species (ROS), in-
cluding dioxygen and hydrogen peroxide (H2O2), which cause
oxidative damage to microorganisms in the phagosome (2, 13).
PMNs fromneonates fail to formNETs when activated by inflam-
matory stimuli and consequently exhibit impaired bactericidal ac-
tivity against extracellular bacteria (13, 41). A variety of different
proinflammatory agonists have been shown to activate NET for-
mation, including the mitogen phorbol myristate acetate (PMA),
bacterial lipopolysaccharide (LPS), and the CXC family chemo-
kine interleukin 8 (IL-8) (4, 13). Such agonists have been reported
to act in activated PMNs via a chemokine receptor pathway (20);
however, the downstream signaling leading to NETosis is not well
understood. Src family kinases and p38mitogen-activated protein
kinases (MAPKs) are activated following stimulation with IL-8.
There is also evidence that IL-8 stimulates phosphatidylinositol-3
kinase (PI3K) activity in human PMNs (23, 24, 32).
The interaction of B. pseudomallei with host cells is known to
be influenced by a bacterial type III secretion system (T3SS), en-
coded by the bsa locus. B. pseudomallei mutants lacking compo-
nents of the Bsa secretion and translocation apparatus, including
bsaZ, bsaQ, bipB, and bipD, are impaired in invasion of epithelial
cells, intracellular net replication, survival inmacrophages, escape
from endocytic vacuoles, and virulence in mice (28–30). Addi-
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tionally, the Bsa T3SS influences the virulence of Burkholderia
mallei (33). A polysaccharide capsule encoded by the wcb operon
also plays a pivotal role in the pathogenesis of murine melioidosis
(37). It has previously been reported that a polysaccharide capsule
protects Streptococcus pneumoniae against entrapment in NETs
(38); however, the role of capsule and of the Bsa T3SS in interac-
tions with human PMN has received little study.
Here, we investigated that role of NETs in the innate response
of human PMNs to B. pseudomallei and of bacterial virulence fac-
tors in counteracting such responses. As we have previously dis-
covered that PMNs from diabetic subjects have impaired antibac-
terial functions (6), we also explored the possibility that NET
formation is altered or impaired in PMNs from DM subjects.
(This work was presented in part at the VI World Melioidosis
Congress, 30 November to 2 December 2010, Townsville,
Queensland, Australia.)
MATERIALS AND METHODS
PMN isolation. Human PMNs were isolated from fresh heparinized ve-
nous blood from healthy and diabetic subjects using the previously re-
ported criteria andmethods (6). Permission was obtained from the Khon
Kaen University Ethics Committee for Human Research, number
HE470506. Briefly, cells were isolated by 3.0% dextran T-500 sedimenta-
tion and separated by Ficoll-Hypaque density gradient centrifugation
(Sigma), followed by hypotonic lysis to remove residual erythrocytes. Pu-
rity was95%, asmeasured by differential count following Giemsa stain-
ing, and viability was99%, as determined by trypan blue exclusion.
Bacterial stains. B. pseudomallei wild-type (WT) strain K96243 is the
prototype strain whose genome has been sequenced (15), and WT strain
10276 was isolated from a fatal case of human melioidosis in Bangladesh
(29). The 10276 bsaZ and K96243 bsaQ mutant strains lacking the func-
tion of the Bsa T3SS have been described elsewhere (21, 29). We also used
K96243 wcbB and wcbN mutants lacking enzymes required for capsule
synthesis as described previously (8). B. pseudomalleiWT strains K96243
and 10276 were grown in Luria-Bertani (LB) broth, whereas type III se-
cretion and capsulemutants were grown in LB broth containing chloram-
phenicol and kanamycin, respectively. The number of viable bacteria used
was determined by retrospective plating of serial 10-fold dilutions on LB
agar plates. The details of the bacteria used in this study are summarized in
Table 1.
Quantification ofNET release.PMNswere incubated for 90minwith
B. pseudomallei WT, mutant strains, or killed B. pseudomallei at a multi-
plicity of infection (MOI) of 10. Typically, the number of bacteria used for
inoculation of 7 log10 PMN cells was 8 log10 CFU. As a positive control,
PMNs were separately treated with 100 nM PMA (Sigma, St. Louis, MO).
Twenty units per milliliter each of restriction enzymes EcoRI andHindIII
(Invitrogen, Paisley, United Kingdom) was added to cultures for NET
digestion for 2 h at 37°C. The activity of restriction enzymes was stopped
with 5 mM EDTA for 15 min at 65°C. Extracellular DNA was then quan-
tified by using a Picogreen double-stranded DNA (dsDNA) kit (Invitro-
gen), in accordance with the manufacturer’s instructions.
NET-mediated bacterial killing. Purified PMNs were placed in 24-
well tissue culture plates and incubated for 30min at 37°C in the presence
and absence of the phagocytosis inhibitor cytochalasin D (10 g/ml;
Sigma). To inhibit NET-mediated bacterial killing, PMNs were incubated
with DNase I (100 units/ml; Invitrogen) for 15 min prior to addition of
bacteria. B. pseudomallei WT K96243 was then added to the PMNs at an
MOI of 10, followed by continued incubation in the presence or absence
of DNase I for 90 min. Infected PMNs were then lysed with 1% Triton
X-100 for 10min, and eachwell was scraped to recover all lysed cells. Serial
dilutions of the lysates were plated to LB agar plates, and bacterial colonies
were counted after 48 h of incubation.
Phagocytosis assay by using flow cytometry.B. pseudomalleiWTand
mutant strains were cultured overnight in LB broth and were adjusted to
1  108 CFU/ml in phosphate-buffered saline (PBS). Bacteria were col-
lected by centrifugation, incubated with 1 g/ml fluorescein isothiocya-
nate (FITC; Sigma) for 60 min at room temperature, and then washed
three times in 1 ml of PBS. The intensity of the FITC signal due to labeled
bacteria was determined prior to use. FITC-labeled bacteria at an MOI of
10were incubated at 37°C for 90min in 5 106 cells/ml of PMNs purified
from healthy donors. Cells were washed twice in ice-cold PBS and then
fixed in 2% (vol/vol) paraformaldehyde in PBS prior to flow cytometric
analysis.
Oxidative burst assay by using flow cytometry.Bacteria at anMOI of
10 were added into 50 l diluted heparinized whole blood at 37°C for 90
min, and 800 ng/ml PMAwas used as a positive control. Dihydroethidium
bromide (Hydroethidine; Sigma) was added to a final concentration of
2,800 ng/ml of blood at 37°C for 5 min. Cells were incubated in 2 ml
fluorescence-activated cell sorter (FACS) lysing solution (BD Bioscience)
to lyse red blood cells, washed twice with PBS, and fixed with 2% (vol/vol)
paraformaldehyde in PBS. Following lysis and fixation, flow cytometric
analysis was performedwith a FACScan flow cytometer by usingCellquest
software (BD Bioscience).
Immunofluorescence assay. PMNs from healthy subjects were incu-
bated at a concentration of 2.5 106 cells/ml with medium control or B.
TABLE 1 Bacterial strains used in this study
Strain Descriptiona Source or reference
B. pseudomallei 10276 Wild-type strain isolated from a human melioidosis patient
in Bangladesh
Ty Pitt, HPA; Stevens et al. (29)
B. pseudomallei K96243 Wild-type strain isolated from a human melioidosis patient
in Thailand
S. Songsivilai, Mahidol, University;
Holden et al. (15)
B. pseudomallei 10276 bsaZ::pDM4 Bsa T3SS structural component mutant; reduced
intracellular replication, absence of membrane
protrusion formation, and delayed ability to escape
endocytic vesicles
Stevens et al. (29)
B. pseudomallei K96243
bsaQ::pKNOCK-Cm
Bsa T3SS structural component mutant; reduced plaque





Transposon mutant, attenuated in BALB/c mouse infection
model but epitope to CPS-I-specific antibody is
maintained
Cuccui et al. (8)
B. pseudomallei K96243
wcbB::mini-Tn5km2
Transposon mutant lacking CPS-I, attenuated in BALB/c
mouse infection model
Cuccui et al. (8)
a MNGCmultinucleated giant cells; CPS-I, capsular polysaccharide I.
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pseudomalleiWT K96243 at an MOI of 10 (unless specified elsewhere) at
37°C for 90 min in the absence or presence of 100 units/ml of DNase I
(Invitrogen). Samples were fixed with 4% (vol/vol) paraformaldehyde
and blockedwith 3% (wt/vol) bovine serumalbumin (BSA; Sigma) in PBS
for 30min at room temperature. Bacteria were stained with a rabbit poly-
clonal anti-B. pseudomallei antibody or mouse polyclonal anti-LPS anti-
body, and primary antibodies were detected bymouse anti-rabbit Ig Alexa
Fluor 488 or a goat anti-mouse IgG Alexa Fluor 568 antibody (Molecular
Probes, Leiden, Netherlands). Histones were stained with a rabbit poly-
clonal anti-histone H3 antibody and a mouse anti-rabbit Ig Alexa Fluor
488 antibody (Molecular Probes) (17). Double-stranded DNA was
stained with propidium iodide (PI) or 4=,6-diamidino-2-phenylindole
(DAPI; Molecular Probes). Stained cells were washed and analyzed by
confocal laser scanning microscopy (LSM 510 META microscope; Carl
Zeiss, Germany).
Treatment of PMNs with inhibitors. The NADPH oxidase inhibitor
diphenyleneiodonium chloride (DPI), the PI3K inhibitor wortmannin,
the p38-MAPK inhibitor SB203580, and the Src family kinase inhibitor
PP2 were purchased from Sigma. The chemokine CXCL8 (IL-8) was pur-
chased from Peprotech (Rocky Hill, NJ). Briefly, PMNs were pretreated
with DPI, wortmannin, SB203580, or PP2 at the doses indicated in the
legend to Fig. 3 at 37°C for 90min, prior to stimulationwith 100 nMPMA,
100 nM recombinant human CXCL8 (IL-8), or B. pseudomallei WT
K96243 at an MOI of 10 at 37°C for 90 min, and NET release was then
quantified as described above.
Statistical analysis. Statistical analysis was performed using tests ap-
propriate to the data set, as specified in the figure legends, and GraphPad
Prism (version 5) software (GraphPad, San Diego, CA). P values of0.05
were considered statistically significant.
RESULTS
B. pseudomallei induces NET formation in time- and dose-de-
pendent manner. We first studied whether NET formation was
induced by B. pseudomallei. The composition of extracellular ma-
terial released by B. pseudomallei-infected human PMNs was an-
alyzed by confocal microscopy. We observed that B. pseudomallei
colocalized with DNA ejected from PMNs which stained with an-
tibody specific for histoneH3 (Fig. 1A toD). Themorphology and
composition of the ejected material are typical of NETs. To deter-
mine whether B. pseudomallei-induced NETs were degraded by
DNase treatment, PMNs from healthy human subjects were in-
fected with B. pseudomallei in the absence or presence of DNase I
enzyme. Compared to uninfected cells (Fig. 1E), propidium io-
dide staining of DNA revealed the release of webs of extracellular
DNA containing trapped bacteria upon B. pseudomallei infection
(Fig. 1F). Treatment of such infected PMNswith DNase I resulted
in the loss of such extracellularDNAnetworks, and the bacteria no
longer appeared to be entrapped (Fig. 1G), suggesting that re-
leased nucleotides were composed of DNA but not RNA.
The kinetics of NET formation were next studied in B. pseu-
domallei-infected PMNs over time and a range of MOIs. Extra-
cellular DNA in culture supernatants was quantified as an
FIG 1 Immunostaining of NETs induced by B. pseudomallei. (A to C) PMNs isolated from healthy control subjects were incubated with B. pseudomallei WT
K96243 at an MOI of 10 for 90 min at 37°C and then stained for DNA with DAPI (A), histones using anti-histone H3 rabbit polyclonal antibody detected with
anti-rabbit Ig Alexa Fluor 488 (B), and bacteria using anti-B. pseudomallei LPS antibody detected with anti-mouse Ig Alexa Fluor 568 (C). (D) Overlay of the
images reveals bacteria trapped in NETs. (E to G) Representative confocal micrographs of uninfected PMNs (E) and PMNs infected with B. pseudomallei for 90
min at 37°C in the absence (F) and presence (G) of 100 units/ml DNase I confirm that bacteria are trapped inDNA-containing networks. For panels E to G, DNA
was stained with PI and bacteria were detected with rabbit anti-B. pseudomallei LPS antibody detected with anti-rabbit Ig Alexa Fluor 488. Photomicrographs are
of representative fields from three independent experiments. (H) The kinetics of B. pseudomallei-induced NET formation over time and at varied MOIs were
assessed by quantifying extracellular DNA using a Picogreen dsDNA kit. Error bars indicate SEMs of three independent experiments. *, P 0.05; **, P 0.01
(ANOVA and Dunnett’s posttest). Magnification512; bars 50 m.
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indicator of NET formation as described in Materials and
Methods. Although the extent of DNA release was comparable
to control levels at an MOI of 0.1 or 0.3, the amount of extra-
cellular DNA released by infected PMNs was significantly in-
creased atMOIs of from 1 to 10 and at 60min postinfection and
time intervals thereafter (Fig. 1H).
NETs kill B. pseudomallei. We next examined the conse-
quences of NET release for B. pseudomallei by quantifying viable
bacteria after infection of PMNs from healthy subjects. Under the
assay conditions, stimulation of the cells with PMA elicited the
release of extracellular DNA relative to the findings for PMNs in
medium alone, as expected (Fig. 2A). Cytochalasin D did not af-
fect the levels of extracellular DNA at the concentration used in
subsequent studies (10 g/ml), and DNase I treatment was con-
firmed to degrade extracellular DNA (Fig. 2A). Upon infection
with WT B. pseudomallei K96243 at an MOI of 10 (Fig. 2B), the
quantity of extracellular DNA released after 90 min was signifi-
cantly increased relative to that released by uninfected cells (Fig.
2A). In addition, DNase I treatment significantly degraded B.
pseudomallei-induced extracellular DNA (Fig. 2B, left y axis). Im-
portantly, the percentage of the inoculumkilled by infected PMNs
fell significantly upon DNase I treatment (Fig. 2B, right y axis),
indicating that a subset of the bacteria is killed by PMNs via NET
formation.
Under the assay conditions used in this study, bacteria may be
killed byNETs and/or by intracellular processes. To separate these
events, infected PMNs were treated with a concentration of cy-
tochalasin D previously reported to substantially reduce entry of
Shigella flexneri into host cells (12). Upon cytochalasin D treat-
ment, the number of bacteria killed fell significantly from approx-
imately 90% (1.0-log10-CFU reduction) for untreated cells (Fig.
2B) to approximately 50% (0.3-log10-CFU reduction) of the ini-
tial inoculum for treated cells (Fig. 2C). Cytochalasin D therefore
promoted survival by preventing uptake and intracellular killing.
Importantly, when the cytochalasin D-treated PMNs infected
with B. pseudomalleiwere treated by DNase I, bacterial killing was
significantly reduced in a manner associated with degradation of
the released DNA (Fig. 2C). This further supports the conclusion
thatNETs have antimicrobial activity against extracellularB. pseu-
domallei.
B. pseudomallei-induced NET formation requires NADPH
oxidase activation. To address the mechanism of NET forma-
tion, we stimulated PMNs with the potent activator PMA and
biologically relevant stimulus IL-8, as well as with B. pseu-
domallei. We then determined whether NADPH oxidase, PI3K,
MAPK, and Src family kinase pathways were involved in NET
formation by using the specific inhibitors DPI, wortmannin,
SB203580, and PP2, respectively. Stimulation with live bacteria
or PMA triggered the induction of NETs, as expected. More-
over, inhibitor pretreatment was not cytotoxic to PMNs at the
concentrations used, as determined by trypan blue exclusion
(data not shown), and the inhibitors did not induce the release
of extracellular DNA at levels that differed from those for the
control (Fig. 3). The DPI, wortmannin, and SB203580 inhibi-
tors reduced the PMA-induced formation of NETs in a dose-
dependent manner (Fig. 3), as previously reported (13, 20, 23).
Moreover, PP2 inhibited IL-8-induced formation of NETs, as
expected (20, 24). Though B. pseudomallei induced the release
of extracellular DNA, this was inhibited by DPI in a dose-de-
pendent and statistically significant manner (analysis of vari-
ance [ANOVA] and Dunnett’s posttest, P  0.01), indicating
that NADPH oxidase is required for efficient NET formation
upon B. pseudomallei infection. Inhibitors of PI3K, MAPK, and
Src family kinase signaling pathways did not significantly affect
NET formation by B. pseudomallei (Fig. 3).
B. pseudomallei bsa andwcbBmutants induce elevated levels
of NET formation. Having demonstrated that wild-type B. pseu-
domallei induces NET formation by human PMNs and that such
NETs exhibit bactericidal activity, we next examined the impact of
mutations affecting known virulence factors of B. pseudomallei in
these processes. Two independent Bsa type III secretion mutants
(K96243 bsaQ and 10276 bsaZ) were used to infect PMNs in par-
allel with the isogenic parent strains for 90 min at an MOI of 10,
and extracellular DNA was quantified. Infection by the bsaQ and
bsaZmutants caused the release of significantlymore extracellular
DNA relative to the amount released by the cognate parent strains
(Fig. 4A). In addition, we observed that the amount of extracel-
lular DNA released by human PMNs was significantly higher
following infection by a wcbB mutant which lacks capsular
polysaccharide I (CPS-I; a chromosome 1-encoded polymer of
FIG 2 B. pseudomallei is killed by NET formation. (A) Purified PMNs pretreated with medium alone, 100 nM the mitogen PMA, 10 g/ml of the phagocytosis
inhibitor cytochalasin D (Cyt D), or 100 units/ml of DNase I after incubation for 90min from control assays for extracellular DNA are shown. (B and C) Release
of extracellular DNA on the left y axis (n 6) and bacterial killing on the right y axis (n 4) at 90min after infection with B. pseudomalleiWTK96243 at anMOI
of 10 are shown. (B) Cells were incubated with 100 units/ml of DNase I or medium for 15 min before the addition of bacteria. (C) Impact of cytochalasin D on
extracellular DNA release and bacterial killing of B. pseudomallei by human PMNs in the presence or absence of DNase I is shown. The horizontal line denotes
the mean SEM. *, P 0.05; **, P 0.01 (paired t test).
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unbranched manno-heptopyranose residues [9]) than infec-
tion by the K96243 parent strain (Fig. 4A). Upon infection by a
wcbN mutant, which lacks the ability to synthesize GDP–D-
glycero--D-manno-heptopyranose and retains an epitope for
a capsule-specific antibody but has reduced virulence in mice
(8, 9), the amount of extracellular DNA released by PMNs was
elevated relative to that released by cells infected by the parent
strain, but not significantly so (Fig. 4A).
To determine if NET induction in these assays required live
bacteria, PMNs were incubated with live or killed B. pseudomallei
for 90 min in the absence or presence of 10g/ml cytochalasin D.
We found that killed B. pseudomallei significantly induced NETs
FIG 3 NADPH oxidase is required for B. pseudomallei-mediated NETs. PMNs from healthy controls were pretreated for 30 min with the NADPH oxidase
inhibitor DPI, the PI3K inhibitor wortmannin, the p38-MAPK inhibitor SB203580, or the Src family kinase inhibitor PP2 and were then stimulated for 90 min
with PMA (100 nM for DPT, wortmannin, and SB203580 treatments), recombinant human CXCL8 (IL-8; 100 nM for PP2 treatment), or B. pseudomallei WT
K96243 at an MOI of 10. The DNA in the supernatants was quantified as described in the text. White bars represent untreated cells (Med; medium only). The
results are for data from one representative of three independent experiments with similar results. The horizontal line denotes the mean SEM. **, P 0.01;
***, P 0.001; ****, P 0.0001 (ANOVA and Dunnett’s posttest).
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compared to live B. pseudomallei. However, after cytochalasin D
treatment, the difference in stimulation ofNET release by killedB.
pseudomallei was not statistically significant (Fig. 4B), suggesting
that NET induction could occur without the uptake of bacteria.
It has been reported that NET formation is dependent on ROS
production (13). To address whether bsa or capsule mutations
exert their effect on NET formation via effects on phagocytosis
and oxidative burst, we performed flow cytometric analysis of
these processes using wild-type and mutant strains. The results
revealed that the B. pseudomallei bsaZ and wcbB mutants were
phagocytosed by PMNs at a significantly higher level than the
cognate parent strain (Fig. 4C). Uptake of the wcbN mutant was
not significantly different from that of the wild type (Fig. 4C). In
addition, the magnitude of the oxidative burst was found to be
significantly elevated for the bsaZ andwcbBmutants compared to
that for the correspondingwild-type strains, whereas the oxidative
burst induced by the wcbN mutant was comparable to that in-
duced by the parent strain (Fig. 4D). Taken together with the
finding that NAPDH oxidase is required for full NET induction,
the results indicated that B. pseudomallei-inducedNET formation
is influenced by the level of phagocytosis and oxidative burst re-
sponse by human PMNs. Moreover, the data imply that the Bsa
T3SS and CPS-I play a role in evading this response. Indeed, we
observed that increased NET induction by the B. pseudomallei
bsaZ and wcbB mutants was associated with increased bacterial
killing of the mutants in the same experiments (see Fig. S1 in the
supplemental material), and this may provide a partial explana-
tion for the role of such factors in virulence.
PMNs fromdiabetesmellitus subjects fail to formNETs.Pre-
viously, we reported the impairment of cellular functions in
FIG 4 Bacterial factors influence NET formation. (A) Extracellular DNA was released from PMNs from healthy subjects (n  6) upon infection by B.
pseudomallei bsa and capsule mutants or their isogenic parent strains at an MOI of 10. (B) Healthy PMNs (n 4) were incubated for 90 min with live or killed
WT B. pseudomallei K96243 at an MOI of 10 in the absence or presence of 10 g/ml cytochalasin D (Cyt D). (C) Isolated PMNs were incubated with medium
alone or FITC-labeled liveWT B. pseudomallei K96243 and its capsule mutant or FITC-labeled liveWT B. pseudomallei 10276 and its bsaZmutant at anMOI of
10 and analyzed by using themean fluorescence intensity (MFI) of FITC-labeled liveB. pseudomallei. (D)Heparinizedwhole-blood samples were incubatedwith
medium alone, 800 ng/ml PMA, or liveWT B. pseudomalleiK96243 and its capsulemutants at anMOI of 10. The oxidative burst was analyzed by using themean
fluorescence intensity of ethidium bromide (EB). The horizontal line denotes the mean  SEM. *, P  0.05; **, P  0.01; ***, P  0.001; ns, nonsignificant
(Mann-Whitney test).
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PMNs from human subjects with diabetes mellitus (6). PMNs
from diabetic subjects were therefore compared to PMNs from
healthy subjects for their ability to release extracellular DNA in
response to PMA stimulation or B. pseudomallei infection. The
results revealed that PMNs from DM patients released signifi-
cantly less extracellular DNA after infection with B. pseudomallei
at anMOI of 3 or 10 than PMNs from healthy controls (Fig. 5). In
addition, PMNs from DM subjects also released significantly
lower quantities of extracellular DNA upon stimulation with
PMA, suggesting that the lower magnitude of the response might
not be specific to their ability to respond to B. pseudomallei. In a
further independent experiment, the reduced formation of NETs
by PMNs from DM subjects compared to healthy controls was
confirmed and could be associated with reduced bacterial killing
under the assay conditions (see Fig. S2 in the supplemental mate-
rial).
DISCUSSION
Neutrophil extracellular traps are a recently described antimicro-
bial mechanism deployed by PMNs. NETs are lattices of extracel-
lular DNA, histones, and antimicrobial proteins released upon
PMN activation that ensnare and kill microorganisms (4, 13).
PMNs play a key role in the control of B. pseudomallei infection
(6), yet the ability of B. pseudomallei to induce or evade NET-
mediated killing is ill defined.Here, we demonstrated thatB. pseu-
domallei infection of human PMNs elicits the release of DNA- and
histone-richNETs fromnaïve PMNswhich are not exposed to any
other stimuli.Moreover, the amount ofDNA released increased in
a time- and dose-dependent manner. DNase I treatment of in-
fected PMNs was observed to degrade the extracellular DNA and
enhance bacterial survival, indicating that NETs have bactericidal
activity against B. pseudomallei. Cytochalasin D treatment indi-
cated that a subset of B. pseudomallei is killed extracellularly by
PMNs, and such killingwas again reduced by dissociation ofNETs
with DNase I.
NADPH oxidase is a membrane-bound enzyme complex
found in the plasma membrane as well as in phagosomal mem-
branes and reported to triggerNETosis, an unique cell death path-
waywhich is distinct fromboth apoptosis and necrosis (2, 13). It is
a highly regulated complex that is capable of producing large
amounts of superoxide that lead to an oxidative burst (2). The
signaling pathways contributing to B. pseudomallei-induced NET
formation were investigated by using the inhibitors DPI, wort-
mannin, SB203580, and PP2. Our data indicate that NAPDH ox-
idase activity is required forNET formation but suggest that PI3K,
MAPK, and Src family kinases are not essential for this process.
DPI has been established to abolish NADPH oxidase-mediated
ROS formation at the concentration used (11); however, we can-
not be certain that this directly impairs NET formation, as super-
oxide generated by NADPH oxidase (Nox) family members may
activate other flavoenzymes, such as xanthine oxidase and NO
synthase, to generate further superoxide (40).
Gram-negative bacterial pathogens of several genera use
type III protein secretion to alter the function of phagocytes
and antigen-presenting cells. Such interference arises from the
injection of bacterial proteins directly into target cells, which
then subvert or inhibit cellular processes to the benefit of the
pathogen. Two independent mutants lacking the function of
the Bsa T3SS elicited the release of higher levels of extracellular
DNA than the parent strain. This was associated with increased
uptake of the bsaZ mutant into PMNs and increased produc-
tion of ROS. Though we speculate that the differences in NET
release by Bsa mutants may be due to differences in the level of
phagocytosis, it is possible that bacterial inhibition of NADPH
oxidase assembly or activity may contribute to the effect. In-
deed, it is known that Salmonella uses a T3SS encoded by Sal-
monella pathogenicity island 2 (SPI-2) to inhibit NADPH oxi-
dase assembly on the membrane of Salmonella-containing
vacuoles, leading to reduced production of ROS and improved
intracellular net replication (14, 36). Moreover, the Yersinia
pestis T3SS inhibits the respiratory burst of human PMNs and
contributes to extracellular survival via the injection of Yop
proteins, albeit intracellular survival of Y. pestis appears to be
independent of T3SS-mediated inhibition of neutrophil ROS
production (26, 27). In contrast to these organisms, B. pseu-
domallei has been reported to rapidly escape from phagosomes,
and further studies are needed to determine if the events de-
scribed above apply during interactions with primary human
PMNs. Moreover, it may be difficult to separate the role of the
Bsa needle in contact-mediated lysis of the phagosomal mem-
brane and escape to the cytosol from the effects of Bsa-secreted
effectors on cellular activities.
It has previously been reported that NETs degrade IpaB of the
Shigella T3SS by proteolysis, thereby disarming the secretion ap-
paratus (12). In vitro B. pseudomallei secretes a number of extra-
cellular enzymes that have the potential to counteract activities
presented in NETs (1). It is conceivable that such products may
counteract the bactericidal activity of NETs. For example, expres-
sion of a surface endonuclease enables S. pneumoniae to degrade
the DNA scaffold of NETs and escape killing (3). While a DNase
has been predicted in B. pseudomallei (19), evidence that this ac-
tivity is secreted or surface associated is lacking.
We also established that capsule-deficient mutants of B. pseu-
domallei induce elevated levels of extracellular DNA upon infec-
tion of PMNs. The response was greater with awcbBmutant com-
pletely lacking the polymer of unbranchedmanno-heptopyranose
residues than with a wcbN mutant that retains a capsule-specific
epitope but whose virulence is attenuated (9). In common with
other encapsulated bacterial pathogens, it appears that theB. pseu-
FIG 5 PMNs from diabetes mellitus patients exhibit impaired B. pseudomal-
lei-induced NET formation. PMNs isolated from healthy control subjects
(HD; n 5) andDMpatients (n 5), whowere defined as having poor or very
poor glycemic control on the basis of the levels of HbA1c (8.5 and 8.5%,
respectively), were stimulated with PMA or WT B. pseudomallei K96243 at an
MOI of 3 or 10 for 90 min at 37°C, and then the amount of extracellular DNA
was quantified by using a Picogreen kit. The horizontal line denotes the
mean SEM. *, P 0.05 (Mann-Whitney test).
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domallei capsule interferes with phagocytosis by human PMNs, as
a wcbB mutant was taken up in higher numbers than either the
parent strain or the wcbN mutant, which retains some capsule.
Following uptake, the wcbB mutant induced a stronger oxidative
burst, which, taken together with the role of NAPDH oxidase in
NET formation,may explainwhy themutant elicited the release of
elevated levels of extracellular DNA.
In a previous report, we demonstrated that PMNs from diabe-
tes mellitus patients are impaired in their ability to phagocytose B.
pseudomallei and to produce an oxidative burst to kill intracellular
bacteria (6). In addition to finding that NET induction can be
influenced by bacterial factors, it is evident from the present study
that PMNs from diabetes mellitus patients are impaired in their
ability to release extracellular DNA in response to B. pseudomallei
infection. Reduced NET formation by PMNs from DM subjects
was associated with reduced bacterial killing relative to that by
PMNs from healthy controls; however, we cannot preclude the
possibility that this may be due to impaired uptake or ROS pro-
duction. Indeed, there was no significant difference in DNA re-
lease between PMA-stimulated PMNs from healthy and diabetic
subjects, suggesting that PMNs from DM patients are not defec-
tive in NET formation per se. Taken together with other defects in
PMN functions, the impairment of NET release may provide a
partial explanation for the elevated susceptibility of diabetes mel-
litus patients to clinical melioidosis and other forms of sepsis.
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